Imiquimod

Overview

Imiquimod is an immune response modifier used topically to treat specific skin diseases, including actinic keratosis, superficial basal cell carcinoma, and external genital warts. It functions by stimulating the body's immune system to release cytokines, which can help destroy viral and cancerous cells.

API suppliers (22)

Suppliers of Imiquimod backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Taro Pharmaceutical Industries Ltd.Israel2 active DMF
• TAPI NL BV1 active DMF
• TAPI NL BV1 active DMF
• ALIVUS LIFE SCIENCES LTD1 active DMF
• WAVELENGTH ENTERPRISES LTDIsrael1 active DMF
• TAPI NL BV1 active DMF
• TAPI NL BV1 active DMF
• WAVELENGTH ENTERPRISES LTDIsrael1 active DMF
• ALIVUS LIFE SCIENCES LTD1 active DMF
• INTERQUIM SA1 active DMF
• USV PRIVATE LTD1 active DMF
• ACTAVIS GROUP PTC EHFIceland1 active DMF
• TAPI NL BV1 active DMF
• WAVELENGTH ENTERPRISES LTDIsrael1 active DMF
• ALIVUS LIFE SCIENCES LTD1 active DMF
• INTERQUIM SA1 active DMF
• USV PRIVATE LTD1 active DMF
• ACTAVIS GROUP PTC EHFIceland1 active DMF
• SOLARA ACTIVE PHARMA SCIENCES LTD1 active DMF
• TAI HENG INDUSTRY CO LTD
• F2 CHEMICALS LTD
• Cipla USA, Inc.USA

Patent & exclusivity (US)

Per the FDA Orange Book (7 approved US products), the latest listed US patent on Imiquimod expires 29 Apr 2030. Generic API sourcing typically opens up once these lapse.

Therapeutic areas